Costa Mesa Firm Gets FDA’s OK to Market an Israeli Cancer Drug
- Share via
International Pharmaceutical Products Inc., a Costa Mesa-based pharmaceutical company, said it has received Food and Drug Administration approval to market Abitrexate, the brand name of a cancer-treatment drug, for an Israeli manufacturer.
The product is the generic equivalent of methotrexate, a drug originally developed by New York-based Lederle Laboratories in 1982.
International Pharmaceutical Products has an exclusive marketing agreement with ABIC Ltd. of Israel, which will manufacture the drug.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
